• Biotechnology
  • Thursday, 03 Oct 2019

Biopharmaceutical Companies Have Increased Their R &D Expenditure in Recent Years

Publisher: The Insight Partners

Increasing Technological Advancements in the CROs Is Expected to Soar the Growth of Pen needles Market from 2018 to 2025.

The global CROs market is experiencing a steep rise in the present scenario and is expected to witness significant growth during the forecast period. The global CROs market was valued at USD 35,818.9 Mn in 2017 and is expected to reach USD 68,198.3 Mn by 2025 with a robust CAGR of 8.6% from 2017 to 2025. The growth of global CROs market is expected to be driven by factors such as increasing chronic diseases such as cancer, Alzheimer’s and other infectious diseases in children that leads to increased R&D activities. Moreover, government funding has increased due to increasing chronic diseases across the globe.

In recent years, there has been a considerable developments in the field of R&D Expenditures and other activities. The biopharmaceutical companies focus on the research and development (R&D) to come up with new molecules for various therapeutic applications with the greatest medical and commercial potential. The R&D spending by the biopharmaceutical companies is significantly increasing. According to a report of Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expenditure of the biopharmaceutical companies has increased from US$49.6 billion 2012 to US$ 58.8 billion in 2015. Moreover, the International Federation of Pharmaceutical Manufacturers & Associations, the R&D expenditures in 2014 by the pharmaceuticals and biotechnology industry grew by approximately 8.7% than that of the expenditures in 2013.

The global CROs market is highly competitive due to the presence of large numbers of players which is attributed to the easy market entry and high profit margins in the market. Some of the prominent players in this market are thus indulged into adoption of inorganic growth strategies such as collaboration and alliances. For instance, in June 2018, Syneos Health and Elligo Health Research entered a strategic collaboration. The collaboration has helped in creating a system of accelerated research that expands our vision of engaging the patient and physician in clinical research

The players operating in the global CROs market include IQVIA, PAREXEL International Corporation, Syneos Health, Laboratory Corporation of America Holdings, PRA Health Sciences, Inc., Charles River, ICON plc, Pharmaceutical Product Development, LLC., WuXi AppTec, Medpaceamong others.


Related News